Establishment of a Novel Anti-Mouse CCR1 Monoclonal Antibody C1Mab-6
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers developed a new antibody, C1Mab-6, targeting mouse C-C motif chemokine receptor 1 (mCCR1). This antibody shows high affinity and specificity, offering a potential tool for modifying the tumor microenvironment (TME) in cancer therapy research.
Area Of Science
- Immunology
- Oncology
- Molecular Biology
Background
- C-C motif chemokine receptor 1 (CCR1) is a G-protein-coupled receptor found on myeloid cells.
- CCR1 signaling in the tumor microenvironment (TME) promotes cancer progression.
- Targeting CCR1 is a promising strategy for cancer therapy, but approved agents are lacking.
Purpose Of The Study
- To develop a novel monoclonal antibody against mouse CCR1 (mCCR1).
- To characterize the specificity and affinity of the developed antibody for potential therapeutic applications.
Main Methods
- Cell-Based Immunization and Screening method used for antibody generation.
- Flow cytometry and Western blot analyses to confirm mCCR1 specificity.
- Determination of dissociation constant (Kd) to assess binding affinity.
Main Results
- A novel anti-mCCR1 monoclonal antibody, C1Mab-6 (rat IgG2b, kappa), was successfully established.
- C1Mab-6 demonstrated specific binding to mCCR1 via flow cytometry and Western blot.
- C1Mab-6 exhibited high affinity for mCCR1, with a dissociation constant of 3.9 × 10⁻⁹ M.
Conclusions
- C1Mab-6 is a highly specific and high-affinity antibody targeting mCCR1.
- This antibody represents a valuable tool for preclinical research involving mCCR1 in mouse models.
- C1Mab-6 holds potential for investigating CCR1-targeted cancer therapies by modulating the TME.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
